RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG)

Catalog #CP155
Clone:
29F.1A12ā„¢-CP155
Reactivities:
Mouse

$217.00 - $5,910.00

$217.00 - $5,910.00

Choose an Option...
  • 100 mg - $5,910.00
  • 50 mg - $4,229.00
  • 25 mg - $2,942.00
  • 5 mg - $843.00
  • 1 mg - $217.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left
Isotype:
Mouse IgG2a
(switched from rat IgG2a)

Product Details

The 29F.1A12ā„¢-CP155 monoclonal antibody is a recombinant chimeric version of the original 29F.1A12ā„¢ antibody. The variable domain sequences are identical to the original 29F.1A12ā„¢ but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. The 29F.1A12ā„¢-CP155 antibody contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous FcĪ³ receptors. 29F.1A12ā„¢-CP155 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1ā€™s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.

Specifications

Isotype Mouse IgG2a,Ā Īŗ
Recommended Isotype Control(s) RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Mutations LALA-PG
Immunogen Recombinant PD-1-Ig fusion protein
Reported Applications in vivo blocking of PD-1/PD-L signaling*
in vitro PD-1 neutralization*
Immunohistochemistry (frozen)*
Immunofluorescence*
Western blot*
Flow cytometry*
*Reported for the original rat IgG2a 29F.1A12 antibody
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <1EU/mg (<0.001EU/Ī¼g)
Determined by LAL gel clotting assay
Sterility 0.2 Āµm filtration
Production Purified from CHO cell supernatant in an animal free facility
Purification Protein G
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze.